117 related articles for article (PubMed ID: 38171245)
1. A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy: Evaluation of dermal safety, intra-mammary drug distribution, and biologic effects.
Lee O; Bazzi LA; Xu Y; Pearson E; Wang M; Hosseini O; Akasha AM; Choi JN; Karlan S; Pilewskie M; Kocherginsky M; Benante K; Helland T; Mellgren G; Dimond E; Perloff M; Heckman-Stoddard BM; Khan SA
Biomed Pharmacother; 2024 Feb; 171():116105. PubMed ID: 38171245
[TBL] [Abstract][Full Text] [Related]
2. Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ: A Randomized Clinical Trial.
Khan SA; Mi X; Xu Y; Blanco LZ; Akasha AM; Pilewskie M; Degnim AC; AlHilli Z; Amin AL; Hwang ES; Guenther JM; Kocherginsky M; Benante K; Zhang S; Helland T; Hustad SS; Gursel DB; Mellgren G; Dimond E; Perloff M; Heckman-Stoddard BM; Lee O
JAMA Surg; 2023 Dec; 158(12):1265-1273. PubMed ID: 37870954
[TBL] [Abstract][Full Text] [Related]
3. Local Transdermal Delivery of Telapristone Acetate Through Breast Skin, Compared With Oral Treatment: A Randomized Double-Blind, Placebo-Controlled Phase II Trial.
Lee O; Pilewskie M; Karlan S; Tull MB; Benante K; Xu Y; Blanco L; Helenowski I; Kocherginsky M; Yadav S; Hosseini O; Hansen N; Bethke K; Muzzio M; Troester MA; Dimond E; Perloff M; Heckman-Stoddard B; Khan SA
Clin Pharmacol Ther; 2021 Mar; 109(3):728-738. PubMed ID: 32996592
[TBL] [Abstract][Full Text] [Related]
4. Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation.
Lee O; Ivancic D; Allu S; Shidfar A; Kenney K; Helenowski I; Sullivan ME; Muzzio M; Scholtens D; Chatterton RT; Bethke KP; Hansen NM; Khan SA
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1235-46. PubMed ID: 26560487
[TBL] [Abstract][Full Text] [Related]
5. Topical Endoxifen for Mammographic Density Reduction-A Randomized Controlled Trial.
Bäcklund M; Eriksson M; Gabrielson M; Hammarström M; Quay S; Bergqvist J; Hellgren R; Czene K; Hall P
Oncologist; 2022 Jul; 27(7):e597-e600. PubMed ID: 35604960
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
[TBL] [Abstract][Full Text] [Related]
7. Value of therapeutic drug monitoring of endoxifen in Egyptian premenopausal patients with breast cancer given tamoxifen adjuvant therapy: A pilot study.
El Desoky ES; Taha AF; Mousa HS; Ibrahim A; Saleh MA; Abdelrady MA; Hareedy MS
J Oncol Pharm Pract; 2023 Oct; 29(7):1673-1686. PubMed ID: 36567618
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.
Lee O; Page K; Ivancic D; Helenowski I; Parini V; Sullivan ME; Margenthaler JA; Chatterton RT; Jovanovic B; Dunn BK; Heckman-Stoddard BM; Foster K; Muzzio M; Shklovskaya J; Skripkauskas S; Kulesza P; Green D; Hansen NM; Bethke KP; Jeruss JS; Bergan R; Khan SA
Clin Cancer Res; 2014 Jul; 20(14):3672-82. PubMed ID: 25028506
[TBL] [Abstract][Full Text] [Related]
9. Orally administered endoxifen is a new therapeutic agent for breast cancer.
Ahmad A; Ali SM; Ahmad MU; Sheikh S; Ahmad I
Breast Cancer Res Treat; 2010 Jul; 122(2):579-84. PubMed ID: 20052538
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
[TBL] [Abstract][Full Text] [Related]
11. First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
Goetz MP; Suman VJ; Reid JM; Northfelt DW; Mahr MA; Ralya AT; Kuffel M; Buhrow SA; Safgren SL; McGovern RM; Black J; Dockter T; Haddad T; Erlichman C; Adjei AA; Visscher D; Chalmers ZR; Frampton G; Kipp BR; Liu MC; Hawse JR; Doroshow JH; Collins JM; Streicher H; Ames MM; Ingle JN
J Clin Oncol; 2017 Oct; 35(30):3391-3400. PubMed ID: 28854070
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
[TBL] [Abstract][Full Text] [Related]
14. Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report.
Henderson SL; Teft WA; Kim RB
BMC Cancer; 2016 May; 16():304. PubMed ID: 27169677
[TBL] [Abstract][Full Text] [Related]
15. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
[TBL] [Abstract][Full Text] [Related]
16. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen Metabolism.
Koubek EJ; Buhrow SA; Safgren SL; Jia L; Goetz MP; Ames MM; Reid JM
Drug Metab Dispos; 2023 Feb; 51(2):183-192. PubMed ID: 36351835
[TBL] [Abstract][Full Text] [Related]
18. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.
Jayaraman S; Reid JM; Hawse JR; Goetz MP
Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34480554
[TBL] [Abstract][Full Text] [Related]
19. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]